Alternative Donor Transplantation for Acute Myeloid Leukemia

Overview

Journal J Clin Med

Specialty General Medicine

Date 2015 Aug 5

PMID 26239557

Citations 4

Authors

Nelli Bejanyan

Housam Haddad

Claudio Brunstein

Affiliations

Soon will be listed here.

Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for adult patients with acute myeloid leukemia (AML), but its use for consolidation therapy after first remission with induction chemotherapy used to be limited to younger patients and those with suitable donors. The median age of AML diagnosis is in the late 60s. With the introduction of reduced-intensity conditioning (RIC), many older adults are now eligible to receive allo-HCT, including those who are medically less fit to receive myeloablative conditioning. Furthermore, AML patients commonly have no human leukocyte antigen (HLA)-identical or medically suitable sibling donor available to proceed with allo-HCT. Technical advances in donor matching, suppression of alloreactivity, and supportive care have made it possible to use alternative donors, such as unrelated umbilical cord blood (UCB) and partially HLA-matched related (haploidentical) donors. Outcomes after alternative donor allo-HCT are now approaching the outcomes observed for conventional allo-HCT with matched related and unrelated donors. Thus, with both UCB and haploidentical donors available, lack of donor should rarely be a limiting factor in offering an allo-HCT to adults with AML.

Citing Articles

Low dose post-transplant cyclophosphamide and sirolimus induce mixed chimerism with CTLA4-Ig or lymphocyte depletion in an MHC-mismatched murine allotransplantation model.

Kabore M, McElrath C, Ali M, Almengo K, Gangaplara A, Fisher C Bone Marrow Transplant. 2024; 59(5):615-624.

PMID: 38347187 PMC: 11073977. DOI: 10.1038/s41409-024-02237-y.

Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation.

Elmariah H, Brunstein C, Bejanyan N Life (Basel). 2021; 11(2).

PMID: 33572932 PMC: 7911120. DOI: 10.3390/life11020102.

Umbilical Cord Blood Transplantation-associated Nephrotic Syndrome Successfully Treated by Low-density Lipoprotein Apheresis.

Sugawara Y, Honda K, Katagiri D, Nakamura M, Kawakami T, Nasu R Intern Med. 2016; 55(19):2831-2836.

PMID: 27725544 PMC: 5088545. DOI: 10.2169/internalmedicine.55.7017.

Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies.

Fabricius W, Ramanathan M Adv Hematol. 2016; 2016:5726132.

PMID: 27034676 PMC: 4789357. DOI: 10.1155/2016/5726132.

References

Brunstein C, Barker J, Weisdorf D, DeFor T, Miller J, Blazar B . Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007; 110(8):3064-70. PMC: 2018678. DOI: 10.1182/blood-2007-04-067215. View

Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A . Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005; 106(13):4397-406. PMC: 1895249. DOI: 10.1182/blood-2005-05-1775. View

Gutman J, Leisenring W, Appelbaum F, Woolfrey A, Delaney C . Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. Biol Blood Marrow Transplant. 2009; 15(9):1122-9. PMC: 2723722. DOI: 10.1016/j.bbmt.2009.05.014. View

Bradstock K, Hertzberg M, Kerridge I, Svennilson J, George B, McGurgan M . Single versus double unrelated umbilical cord blood units for allogeneic transplantation in adults with advanced haematological malignancies: a retrospective comparison of outcomes. Intern Med J. 2009; 39(11):744-51. DOI: 10.1111/j.1445-5994.2008.01825.x. View

Rocha V, Cornish J, Sievers E, Filipovich A, Locatelli F, Peters C . Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001; 97(10):2962-71. DOI: 10.1182/blood.v97.10.2962. View

Lu D, Dong L, Wu T, Huang X, Zhang M, Han W . Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2005; 107(8):3065-73. DOI: 10.1182/blood-2005-05-2146. View

Ballen K, Spitzer T, Yeap B, McAfee S, Dey B, Attar E . Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007; 13(1):82-9. PMC: 2947324. DOI: 10.1016/j.bbmt.2006.08.041. View

Brunstein C, Miller J, Cao Q, McKenna D, Hippen K, Curtsinger J . Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2010; 117(3):1061-70. PMC: 3035067. DOI: 10.1182/blood-2010-07-293795. View

Locatelli F, Perotti C, Torretta L, Maccario R, Montagna D, Ravelli A . Mobilization and selection of peripheral blood hematopoietic progenitors in children with systemic sclerosis. Haematologica. 1999; 84(9):839-43. View

10.

Gladstone D, Zachary A, Fuchs E, Luznik L, Kasamon Y, King K . Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant. 2013; 19(4):647-52. PMC: 3768172. DOI: 10.1016/j.bbmt.2013.01.016. View

11.

Lafferty K, Cunningham A . A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci. 1975; 53(1):27-42. DOI: 10.1038/icb.1975.3. View

12.

OReilly R, Keever C, Kernan N, Brochstein J, Collins N, Flomenberg N . HLA nonidentical T cell depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency disease. Transplant Proc. 1987; 19(6 Suppl 7):55-60. View

13.

Ruggeri A, Sanz G, Bittencourt H, Sanz J, Rambaldi A, Volt F . Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of.... Leukemia. 2013; 28(4):779-86. DOI: 10.1038/leu.2013.259. View

14.

Comoli P, Schilham M, Basso S, van Vreeswijk T, Bernardo M, Maccario R . T-cell lines specific for peptides of adenovirus hexon protein and devoid of alloreactivity against recipient cells can be obtained from HLA-haploidentical donors. J Immunother. 2008; 31(6):529-36. DOI: 10.1097/CJI.0b013e31817b9c6b. View

15.

Ciurea S, Mulanovich V, Saliba R, Bayraktar U, Jiang Y, Bassett R . Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012; 18(12):1835-44. PMC: 4320643. DOI: 10.1016/j.bbmt.2012.07.003. View

16.

Appelbaum F, Anasetti C, Antin J, Atkins H, Davies S, Devine S . Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Transplant. 2014; 21(2):202-24. PMC: 4426907. DOI: 10.1016/j.bbmt.2014.10.003. View

17.

Grosso D, Gaballa S, Alpdogan O, Carabasi M, Filicko-OHara J, Kasner M . A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease. Biol Blood Marrow Transplant. 2014; 21(4):646-52. DOI: 10.1016/j.bbmt.2014.12.019. View

18.

Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M . Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning.... Blood. 2006; 109(3):1322-30. DOI: 10.1182/blood-2006-04-020172. View

19.

Rio B, Chevret S, Vigouroux S, Chevallier P, Furst S, Sirvent A . Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial. Biol Blood Marrow Transplant. 2014; 21(3):445-53. DOI: 10.1016/j.bbmt.2014.11.009. View

20.

Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo M . Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007; 7(6):1648-55. DOI: 10.1111/j.1600-6143.2007.01823.x. View